MAXHEALTH - Max Healthcare
📢 Recent Corporate Announcements
Max Healthcare Institute Limited has announced its participation in the J.P. Morgan India Forum 2026. The event is scheduled for March 9 and 10, 2026, and will be held physically at the Fullerton Hotel in Singapore. The company's Chairman and Managing Director will lead the engagement, conducting both one-on-one and group meetings with institutional investors. The company has clarified that no unpublished price sensitive information will be shared during these interactions.
- Investor conference scheduled for March 9 and 10, 2026, in Singapore.
- Chairman and Managing Director to represent the company in one-on-one and group meetings.
- Participation in the J.P. Morgan India Forum 2026 to engage with global institutional investors.
- Company confirms no unpublished price sensitive information (UPSI) will be disclosed.
Max Healthcare Institute Limited has received a partially favorable appeal order from the Commissioner of Central Tax Appeal-II, Delhi. The original GST demand for the period FY 2017-18 to FY 2020-21, which totaled approximately ₹5.13 crore including penalties, has been significantly reduced. The revised demand now stands at approximately ₹1.77 crore, including GST, interest, and penalties. The company intends to file a further appeal to contest the remaining balance of the demand.
- Appeal order deleted tax demand of ₹1.67 crore and penalty of ₹1.68 crore from the original assessment.
- Total revised demand stands at ₹1.77 crore, down from the previous demand of over ₹5.13 crore.
- The dispute relates to alleged discrepancies in Input Tax Credit (ITC) and tax recovery for FY 2017-18 to FY 2020-21.
- Management confirms no other material impact on financial or operational activities and will pursue further appeals.
Max Healthcare showcased its position as India's largest hospital chain by market cap (₹1.02 lakh crore) with a strong 4-year EBITDA CAGR of 38% and Revenue CAGR of 24%. The company currently operates over 5,200 beds across 20 facilities, maintaining a high occupancy rate of 76% and a robust ROCE of 26% for 9M FY26. Growth is being driven by aggressive inorganic expansion, including recent acquisitions in Lucknow, Nagpur, and Noida, alongside significant brownfield expansions in Mumbai and Mohali.
- Achieved a 38% EBITDA CAGR and 24% Revenue CAGR over the last 4 years (FY21-FY25)
- Current capacity exceeds 5,200 beds with 73% located in high-demand metro areas
- Maintained a strong Return on Capital Employed (ROCE) of approximately 26% for 9M FY26
- Institutional investors (FIIs and DIIs) hold a combined stake of over 71% as of December 2025
- Ongoing expansion includes a 160-bed tower in Mohali and a 268-bed tower at Nanavati-Max
Max Healthcare reported a 10% YoY revenue growth to INR 2,608 crore for Q3 FY26, although operating EBITDA margins contracted to 26.1% from 27.3% YoY. Performance was impacted by transitory factors including a temporary disruption in cashless services with insurers and revised CGHS pricing for chemotherapy drugs. Despite these headwinds, occupancy remained healthy at 74% on an expanded bed base, and ARPOB grew 3% YoY to INR 77,900. The company continues its aggressive expansion with new beds commissioned in Mumbai and Mohali, and a board-approved 260-bed addition at Max Dwarka.
- Gross revenue increased 10% YoY to INR 2,608 crore, while operating EBITDA grew 4% to INR 648 crore.
- Average Revenue Per Occupied Bed (ARPOB) reached INR 77,900, reflecting a 3% YoY growth.
- International patient revenue grew 14% YoY, now accounting for 9% of total hospital revenue.
- Brownfield expansion is on track with 116 beds commissioned across Nanavati and Mohali units in Q3.
- Net debt-to-EBITDA remains conservative at less than 1x, with INR 281 crore free cash flow generated during the quarter.
Max Healthcare Institute Limited (MAXHEALTH) released its latest investor presentation, highlighting its position as India's largest hospital chain by market capitalization at ₹1.02 lakh crore. The company demonstrated robust financial performance with a 4-year EBITDA CAGR of 38% and a revenue CAGR of 24%. Operational efficiency remains high with a 9M FY26 occupancy rate of approximately 76% and a Return on Capital Employed (ROCE) of 26%. The presentation outlines a massive expansion pipeline across Delhi NCR, Mumbai, Lucknow, and Pune to further scale its 5,200+ bed capacity.
- Market capitalization stands at ₹1.02 lakh crore ($11.3 billion) as of December 31, 2025.
- Achieved a 38% EBITDA CAGR and 24% Revenue CAGR over the last 4 years.
- Current capacity exceeds 5,200 beds across 20 facilities with 73% of beds located in metro cities.
- Maintained strong operational metrics with ~76% occupancy and ~26% ROCE for 9M FY26.
- Significant expansion pipeline includes a ~1,000-bed project in Gurugram and a ~450-bed hospital development in Pune.
Max Healthcare Institute Limited has informed the exchanges that the audio recording of its earnings call held on February 6, 2026, is now available for public access. The call focused on the company's financial performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is a routine regulatory requirement under SEBI (LODR) Regulations, 2015. Investors can access the full recording on the company's official website to understand management's outlook on the healthcare sector and specific operational metrics.
- Audio recording of the earnings call held on February 6, 2026, is now live on the company website.
- The call discussed financial results for the quarter and nine months ended December 31, 2025.
- Compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Recording provides insights into management's commentary on recent quarterly performance.
Max Healthcare reported a steady Q3 FY26 with gross revenue rising 10% YoY to ₹2,608 Cr, supported by a 7% growth in occupied bed days. Network Operating EBITDA grew 4% YoY to ₹648 Cr, though margins saw a slight compression to 26.1% due to pre-commissioning expenses and regulatory shifts. PAT increased 9% YoY to ₹344 Cr, even after accounting for ₹55 Cr in exceptional items related to labor codes and stamp duties. The company is actively expanding, having commissioned new beds in Mohali and Mumbai while announcing a new 450-bed project in Pune.
- Gross Revenue grew 10% YoY to ₹2,608 Cr; Network PAT increased 9% YoY to ₹344 Cr.
- ARPOB improved to ₹77.9k from ₹75.9k YoY, while bed occupancy stood at 74%.
- Successfully commissioned 53 beds in Mohali and 63 beds in Nanavati Max with healthy initial margins of 39% and 31% respectively.
- Announced staggered acquisition of Yerawada Properties in Pune for a new ~450-bed hospital project.
- Exceptional charges of ₹55 Cr impacted the bottom line, alongside temporary headwinds from CGHS tariff revisions and drug pricing guidelines.
Max Healthcare reported a steady Q3 FY26 with a 10% YoY revenue growth to ₹2,608 Cr and a 9% rise in PAT to ₹344 Cr, despite ₹55 Cr in exceptional charges. Operating margins compressed slightly to 26.1% from 27.3% due to pre-commissioning expenses for new beds and regulatory impacts on institutional drug pricing. The company is aggressively expanding, with new brownfield beds already operational in Mohali and Nanavati showing strong initial margins. Operational metrics remain healthy with ARPOB increasing to ₹77.9k and bed occupancy at 74%.
- Gross Revenue grew 10% YoY to ₹2,608 Cr, while Network Operating EBITDA rose 4% YoY to ₹648 Cr.
- PAT increased 9% YoY to ₹344 Cr after accounting for ₹55 Cr in exceptional items related to wage codes and stamp duty.
- ARPOB (Average Revenue Per Occupied Bed) improved to ₹77.9k, while bed occupancy stood at 74%.
- Newly commissioned beds in Mohali (53 beds) and Nanavati (63 beds) delivered healthy EBITDA margins of 39% and 31% respectively.
- Announced a new 450-bed hospital project in Pune via the acquisition of Yerawada Properties Pvt. Ltd.
Max Healthcare Institute reported a steady performance for Q3 FY26 with consolidated revenue growing 10.7% YoY to ₹2,067.5 crore. Net profit (PAT) saw a robust 26% YoY increase to ₹300.9 crore, despite an exceptional charge of ₹48.2 crore during the quarter. The company is aggressively pursuing growth, evidenced by the board's approval to add ~260 beds to its Dwarka facility, nearly doubling its current 300-bed capacity. While sequential (QoQ) performance showed a slight dip in revenue and profit, the nine-month PAT growth of 45% YoY highlights strong operational momentum.
- Consolidated Revenue from operations increased 10.7% YoY to ₹2,06,752 Lakhs.
- Net Profit (PAT) for the quarter rose 26% YoY to ₹30,092 Lakhs from ₹23,880 Lakhs.
- Board approved expansion of Max Super Speciality Hospital, Dwarka by adding ~260 additional beds.
- Nine-month (9M FY26) PAT reached ₹1,10,019 Lakhs, a 45% increase over the previous year's ₹75,688 Lakhs.
- Exceptional item of ₹4,824 Lakhs recorded in Q3 FY26, impacting the pre-tax profit.
Max Healthcare Institute Limited has approved the grant of 2,84,520 stock options to eligible employees under its 2022 ESOP scheme. The grant is divided into two tranches with exercise prices of ₹900 and ₹800 per share respectively. These options will vest over a period of 1 to 5 years, depending on the fulfillment of pre-vesting conditions. This action is a standard procedure for talent retention and aligning employee interests with company performance.
- Total grant of 2,84,520 stock options convertible into an equal number of equity shares
- 2,34,520 options granted at an exercise price of ₹900 per share
- 50,000 options granted at a lower exercise price of ₹800 per share
- Vesting period ranges from a minimum of 1 year to a maximum of 5 years from the grant date
- Exercise period is 3 years from the date of each vesting
Max Healthcare Institute Limited has approved the grant of 2,84,520 stock options to eligible employees under its 2022 ESOP scheme. The grant is split into two tranches with exercise prices set at ₹900 for 2,34,520 options and ₹800 for 50,000 options. These options will vest over a period of one to five years, contingent on meeting specific pre-vesting conditions. This move is a standard corporate practice aimed at talent retention and aligning employee incentives with long-term shareholder interests.
- Total grant of 2,84,520 stock options convertible into an equal number of equity shares
- Exercise price fixed at ₹900 per option for 2,34,520 units and ₹800 per option for 50,000 units
- Vesting period ranges from a minimum of 1 year to a maximum of 5 years from the grant date
- Exercise period is 3 years from the date of respective vesting
- The grant was approved by the Nomination and Remuneration Committee on February 4, 2026
Max Healthcare Institute Limited has announced its participation in two major institutional investor conferences scheduled for February 2026. The company's Chairman, Managing Director, and Senior Management will engage with investors at the Nuvama India Conference on February 9 and the 17th Kotak Chasing Growth Conference on February 23. Both events will take place in Mumbai and involve one-on-one and group meetings. While no unpublished price sensitive information will be shared, these meetings are key for institutional engagement.
- Participation in Nuvama India Conference 2026 on February 9, 2026, in Mumbai.
- Participation in 17th Kotak Chasing Growth Conference 2026 on February 23, 2026.
- Senior management including the Chairman and MD to lead the physical meetings.
- Meetings will include both one-on-one and group interaction formats.
- Company confirms no unpublished price sensitive information (UPSI) will be disclosed.
Max Healthcare Institute has started the voluntary liquidation process for its wholly-owned subsidiary, MHC Global Healthcare (Nigeria) Limited. The subsidiary is considered non-material, having contributed zero revenue to the consolidated financials as of March 31, 2025. Its net worth contribution was a negative ₹70.90 lakhs, representing a negligible -0.0076% of the group's total net worth. The company expects no material impact on its consolidated financial performance or business operations from this move.
- MHC Global Healthcare (Nigeria) Limited contributed ₹0 to the consolidated revenue in FY25.
- The subsidiary's net worth was negative ₹70,89,724, accounting for only -0.0076% of the group's net worth.
- The liquidation is voluntary and will not affect the company's core business operations or financials.
- The process has been initiated with the Corporate Affairs Commission and other relevant authorities in Nigeria.
Max Healthcare Institute Limited has scheduled its Q3 and 9M FY26 earnings conference call for February 6, 2026, at 11:30 AM IST. The financial results for the period ending December 31, 2025, will be officially declared on February 5, 2026. The company currently operates a network of 20 healthcare facilities with approximately 5,200 beds across India. Senior management will provide commentary on financial performance and strategic initiatives during the interactive session.
- Earnings call set for Feb 6, 2026, following result declaration on Feb 5, 2026
- Company manages a significant footprint of 20 healthcare facilities and ~5,200 beds
- Discussion to include performance of core hospitals, Max@Home, and Max Labs diagnostic services
- Dial-in details provided for international investors in HK, Singapore, UK, and USA
Max Healthcare Institute Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The company's registrar, MUFG Intime India Private Limited, confirmed that no requests for dematerialization of shares were received during the quarter ended December 31, 2025. The filing also notes that the company currently has no physical shares in circulation. This is a standard procedural disclosure required for all listed entities in India.
- Compliance certificate issued for the quarter ending December 31, 2025.
- Zero dematerialization requests were received or processed during the quarter.
- Registrar confirmed that Max Healthcare Institute Limited has no physical shares.
- The filing was made in accordance with SEBI (Depositories and Participants) Regulations, 2018.
Financial Performance
Revenue Growth by Segment
Standalone revenue from operations grew 13.8% to INR 2,663.60 Cr in FY25. Healthcare services contributed INR 2,411.33 Cr (90.5% of standalone revenue), Operation and Management (O&M) fees contributed INR 86.86 Cr (3.3%), and pharmaceutical supply sales contributed INR 108.63 Cr (4.1%). Consolidated network revenue grew 16% in FY24 and 21% YoY in Q2 FY26.
Geographic Revenue Split
The company has a high geographic concentration with approximately 75% to 78% of its bed capacity located in metro cities, specifically the Delhi-NCR region. The remaining capacity is distributed across Mumbai, Mohali, Lucknow, and Nagpur.
Profitability Margins
Consolidated operating margins stood at 28.23% in FY24, an improvement from 27.19% in FY23. Standalone other income increased to INR 366.54 Cr in FY25, supporting net profitability. Max Lab (diagnostics) reports an EBITDA margin of 16%, while Max@Home reports approximately 20%.
EBITDA Margin
Consolidated operating EBITDA increased by 23% YoY in Q2 FY26. The MHC network operating margin was 26.87% in FY24. Profitability is driven by a 12.5% increase in Average Revenue Per Occupied Bed (ARPOB), which rose from INR 67,400 in FY23 to INR 75,800 in FY24.
Capital Expenditure
The company plans to double its capacity over the next five years through organic and inorganic routes. A significant recent investment includes the acquisition of the remaining 36.35% stake in JHL for INR 624.70 Cr in November 2024. Expansion is largely funded through internal accruals.
Credit Rating & Borrowing
Long-term bank facilities (INR 871.01 Cr) are rated CARE AA+; Stable (upgraded from CARE AA; Positive in Oct 2024). Short-term facilities (INR 80.00 Cr) are rated CARE A1+. Net leverage stood at 1.43x as of March 31, 2025.
Operational Drivers
Raw Materials
Medical consumables, pharmaceutical supplies, and surgical implants represent the primary variable costs, though specific percentage breakdowns per item are not disclosed. Pharmaceutical sales alone accounted for INR 108.63 Cr of standalone revenue.
Import Sources
Not disclosed in available documents; however, procurement is managed through a centralized digital platform to ensure consistency across the 22 facilities.
Key Suppliers
Not specifically named; procurement is governed by robust internal financial control systems and standard operating procedures (SOPs).
Capacity Expansion
Current network consists of 22 facilities (hospitals and medical centers) as of March 31, 2025, up from 17 in the previous year. The company aims to double this capacity within 5 years. Max Dwarka added 303 beds and achieved EBITDA breakeven within 6 months.
Raw Material Costs
Not explicitly disclosed as a % of revenue, but the company utilizes 'Revenue Cycle Management' to minimize leakage and manage the cost of pharmaceutical supplies which are sold as part of the healthcare service.
Manufacturing Efficiency
Network occupancy levels stood at 74.5% in FY24 (compared to 76.4% in FY23). Efficiency is measured by ARPOB growth (up 12.5% YoY) and the rapid breakeven of new facilities like Dwarka.
Logistics & Distribution
Distribution of services is managed through an omnichannel digital platform, Max MyHealth, which has 9.5 Lakh registrations and 1.15 Lakh monthly active users.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
Growth will be achieved by doubling bed capacity over 5 years through organic expansions and M&A (e.g., Lucknow and Nagpur acquisitions). The company is also scaling asset-light models (O&M agreements like Max Dwarka) and digital platforms (Max MyHealth) to increase patient reach without heavy capital intensity.
Products & Services
Quaternary care healthcare services, inpatient procedures (2.90 Lakh in FY25), outpatient consultations (24.2 Lakh in FY25), day care procedures (0.8 Lakh in FY25), diagnostic services (Max Lab), and home healthcare (Max@Home).
Brand Portfolio
Max Healthcare, Max Lab, Max@Home, Max MyHealth, Max Healthcare Foundation.
New Products/Services
Expansion of Max Lab and Max@Home segments; Max@Home currently maintains a 20% EBITDA margin and is expected to scale rapidly.
Market Expansion
Expansion into non-metro high-growth markets including Lucknow, Nagpur, and Mohali to de-risk from Delhi-NCR concentration.
Market Share & Ranking
India's largest hospital chain by market capitalization (INR 1.1 Lakh Cr) and second largest by Revenue and EBITDA.
Strategic Alliances
O&M agreement with Muthoot Hospitals Private Limited for the 303-bed Dwarka facility; partnership with various healthcare societies (Devki Devi, Gujarmal Modi, Balaji, Lahore Hospital Society).
External Factors
Industry Trends
The industry is shifting toward digital health (omnichannel platforms) and consolidation. Max is positioned as a leader with its Max MyHealth platform and aggressive M&A strategy to capture market share in a growing but competitive sector.
Competitive Landscape
Intense competition from other established hospital brands in metro micro-markets (Noida, Lucknow, Mumbai) where capacity addition may temporarily outpace demand.
Competitive Moat
Moat is built on high brand equity ('Max Healthcare'), a dominant 75%+ position in the lucrative Delhi-NCR market, and a high-value specialty mix that drives industry-leading ARPOB. Sustainability is supported by the high switching costs of specialized quaternary care.
Macro Economic Sensitivity
Sensitive to healthcare regulatory changes and price caps on medical procedures/consumables which can constrain profitability.
Consumer Behavior
Increasing preference for digital engagement (9.5 Lakh digital registrations) and home-based healthcare services (Max@Home).
Geopolitical Risks
Minimal direct impact as operations are domestic, but global medical tourism trends affect patient volumes.
Regulatory & Governance
Industry Regulations
Subject to healthcare pricing regulations and pollution norms for biomedical waste. The company proactively engages with NATHEALTH and FICCI to influence policy discussions.
Environmental Compliance
Focus on achieving 'water neutrality' through water recharge and rejuvenation initiatives; CSR activities are managed via the Max Healthcare Foundation.
Taxation Policy Impact
The company follows Indian Accounting Standards (Ind AS). Specific effective tax rate % is not disclosed in the snippets.
Legal Contingencies
The company has a vigil mechanism and Whistle Blower Policy to report concerns. Specific pending court case values in INR are not disclosed in the provided documents.
Risk Analysis
Key Uncertainties
Regulatory intervention in healthcare pricing could impact margins; potential under-utilization of new capacity if demand growth slows in metro markets.
Geographic Concentration Risk
75% to 78% of bed capacity is concentrated in Delhi-NCR, making the company vulnerable to regional economic or regulatory shifts.
Third Party Dependencies
Dependency on Partner Healthcare Facilities (PHFs) and societies for O&M models, though rights are typically 'exclusive and irrevocable'.
Technology Obsolescence Risk
Risk of falling behind in medical technology; mitigated by continuous investment in 'state-of-the-art technology' and digital platforms.
Credit & Counterparty Risk
Complexity in billing systems for insurance/institutional payors increases the risk of revenue leakage and disputes; mitigated by robust revenue cycle management.